Harmony Biosciences Holdings, Inc. Common Stock
$42.02
-$0.72 (-1.68%)
$41.90Day Range$43.27
Key Statistics
Market Cap
$2.49B
Shares Outstanding
58.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 19, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$42.57
Day High
$43.27
Day Low
$41.90
Volume
3.82M
VWAP
$42.27
Prev Close
$42.74
Transactions
--
Acc. Volume
--
About Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
PHARMACEUTICAL PREPARATIONSSIC 2834293 employees630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462(484) 539-9800IPO Aug 19, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001802665
- Composite FIGI
- BBG00WBPG4C2
- Share Class FIGI
- BBG00WBPG548
- Ticker Root
- HRMY
- SIC Code
- 2834
About Harmony Biosciences Holdings, Inc. Common Stock (HRMY) Stock
Harmony Biosciences Holdings, Inc. Common Stock (HRMY) closed the 2026-09-18 session at $42.02, down 1.68% versus the previous close (-0.72). The stock opened at $42.57 and traded between $41.90 and $43.27 during that session. Session trading volume was 3.8M shares. The volume-weighted average price (VWAP) is $42.27.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Harmony Biosciences Holdings, Inc. Common Stock has a market capitalization of $2.49 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. HRMY is listed on the XNAS exchange. The company employs approximately 293 people. Harmony Biosciences Holdings, Inc. Common Stock is headquartered in PLYMOUTH MEETING, PA. The recorded listing date is 2020-08-19.
On this page you can find market HRMY stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.